Clinical Trial Update: Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) [Phase 2]

View source ↗

Summary

Phase 2 study comparing ruxolitinib to anagrelide in essential thrombocythemia patients resistant to or intolerant of hydroxyurea; the trial status is terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myeloproliferative Neoplasms

Drugs mentioned

• ANAGRELIDE (Anagrelide)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: MPN (Myeloproliferative Neoplasms) | Phase 2 | Status: TERMINATED | Results posted: 2021-11-19